Q-omics provides the consensus-scored KRTAP12-6P profile across patient tissues and cancer cell-line models. KRTAP12-6P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, KRTAP12-6P is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, KRTAP12-6P RNA expression shows 5,502 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, THCA, and TGCT as cancer lineages where KRTAP12-6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP12-6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP12-6P survival associations across molecular data types. KRTAP12-6P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP12-6P RNA expression–survival associations across cancer types. High KRTAP12-6P expression shows unfavorable associations in BLCA, THCA, OV, READ and HNSC, but favorable associations in LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for KRTAP12-6P RNA expression.
This table summarizes KRTAP12-6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP12-6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP12-6P shows lower tumor expression in THCA. The THCA box plot shows higher KRTAP12-6P RNA expression in normal versus tumor tissue (log2 FC = −0.024, t-test p = .041).
This table shows molecular features associated with KRTAP12-6P in patient tissues and cancer cell lines. In patient samples, KRTAP12-6P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
